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Depression and anxiety associate with less 
remission after 1 year in rheumatoid arthritis
Depression and anxiety have been considered to influence 
disease activity, and with great interest we read the recently 
published report by Michelsen et al.1 In this large, prospective, 
multicentre observational study, depression and anxiety reduced 
the likelihood of joint remission based on composite scores, in 
rheumatoid arthritis (RA) after 3 and 6 months. Differences were 
predominantly caused by subjective markers of disease activity 
rather than by C reactive protein or erythrocyte sedimentation 
rate. The study cannot prove causality; however, their findings 
imply that baseline depression/anxiety can impair the fulfilment 
of remission criteria during follow-up, influencing important 
treatment decisions.
As replication is a keystone in research, we aimed to validate 
their findings in an independent cohort, the Leiden Early Arthritis 
Clinic (EAC), to assess generalisability of the results. The EAC is 
a population-based inception cohort of patients with newly diag-
nosed arthritis that started in 1993; from 2010 onwards patients 
completed the Short Form-36 (SF-36) at baseline.2 We studied 
patients included between 2010 and 2014 who fulfilled the 2010 
criteria for RA (n=343) and selected patients who completed 
the SF-36 (n=293). Patients with RA were treated according 
to the insight of the treating rheumatologist: standard therapy 
regimen consists of early initiation with methotrexate; in case 
of failure a second synthetic disease-modifying antirheumatic 
drug (DMARD) was prescribed and in case of failure a biologic 
DMARD was allowed.3 Outcome of joint remission was 44-joint 
Disease Activity Score (DAS44 ≤2.4) after 1 year.4 5 Similar as 
Michelsen et al we identified depression/anxiety by the SF-36 
mental health subscale (MH ≤56) and SF-36 mental component 
summary (MCS ≤38).
Baseline characteristics are shown in table 1. The percentage 
of depressed/anxious patients with RA was 20% according to 
the SF-36 MCS ≤38 and 23% according to the SF-36 MH ≤56. 
Anxious/depressed patients were significantly younger and had 
a higher patient global assessment (table 1). Anxiety and depres-
sion were negatively associated with achieving DAS remission 
after 1 year, analysed with logistic regression models corrected 
for age, gender and symptom duration (OR, 0.21, 95% CI 0.09 
to 0.46 for MCS; OR, 0.24, 95% CI 0.11 to 0.51 for MH; 
P<0.001; figure 1). Analyses with additional correction for base-
line DAS showed similar results (MCS P<0.001; MH P=0.001). 
Further analyses on features of disease activity at year 1 showed 
that anxiety/depression was associated with more pain (β=12.1, 
P<0.001 for MCS; β=11.1, P=0.03 for MH) and a trend for 
a higher patient global assessment (β=9.0, P=0.07 for MCS).
Thus, our study on the association of baseline anxiety and 
depression with remission after 1 year validated the findings 
from Michelsen et al. We observed higher percentages of patients 
with RA in DAS remission, which could be caused by the longer 
duration of treatment (evaluation of remission at 1 year, instead 
of 3 and 6 months by Michelsen et al).
Concluding, baseline depression and anxiety are associated 
with a lower chance to achieve DAS remission, which was mostly 
reflected by associations with subjective features of disease 
activity. Also our study cannot prove causality, although the asso-
ciation between the mental state and DAS components suggests 
that efforts to improve the psychological well-being early in the 
disease course may prevent higher DAS scores later on. This 
could potentially prevent increased medical costs due to more 
intensified treatment strategies.
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Table 1 Baseline characteristics of patients with rheumatoid 
arthritis with versus without baseline depression/anxiety according to 









Age, mean (SD) 57 (15) 54 (15) 58 (14) 0.02
Female, n (%) 193 (66) 58 (72) 135 (64) 0.20
Symptom duration in 
months, median (IQR)
3 (1–8) 3 (1–7) 3 (1–8) 0.72
Currently smoking, n (%) 65 (23) 25 (33) 40 (20) 0.08
ACPA-positive, n (%) 162 (55) 43 (53) 119 (56) 0.64
ESR (mm/hour), median 
(IQR)
28 (14–41) 28 (14–42) 28 (14–41) 0.85
CRP (mg/L), median 
(IQR)
10 (3–22) 7 (3–26) 10 (3–20) 0.76
EGA, mean (SD) 49 (20) 49 (24) 49 (19) 0.44
PGA, mean (SD) 45 (27) 54 (27) 42 (26) 0.001
Pain, mean (SD) 60 (25) 63 (24) 58 (25) 0.92
68-TJC, median (IQR) 10 (5–17) 11 (6–19) 10 (5–16) 0.18
66-SJC, median (IQR) 5 (2–11) 5 (2–10) 6 (2–11) 0.14
DAS44, mean (SD) 2.9 (0.8) 3.0 (0.8) 2.9 (0.8) 0.45
Pain measured by a 0–100 VAS.
68-TJC, 68 tender joint counts; 66-SJC, 66 swollen joint counts; ACPA, 
anticitrullinated peptide antibody; CRP, C reactive protein; DAS44, 44-joint Disease 
Activity Score; EGA, evaluator’s global assessment by a 0–100 VAS; ESR, erythrocyte 
sedimentation rate; MCS, mental component summary; MH, mental health subscale; 
PGA, patient’s global assessment by a 0–100 VAS; VAS, Visual Analogue Scale. 
Figure 1 Percentages of patients with RA in remission at 1 year 
(DAS44 ≤2.4) who did or did not have depression/anxiety at the time of 
diagnosis.
DAS44, 44-joint Disease Activity Score; RA, rheumatoid arthritis; SF-
36 MCS, Medical Outcomes Survey Short Form-36 mental component 
summary; SF-36 MH, Medical Outcomes Survey Short Form-36 mental 
health subscale.
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